{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T10:39:02Z","timestamp":1768732742359,"version":"3.49.0"},"reference-count":85,"publisher":"Informa UK Limited","issue":"10","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81273375 and 21372260"],"award-info":[{"award-number":["81273375 and 21372260"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Med. Chem."],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.4155\/fmc-2017-0001","type":"journal-article","created":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T16:23:02Z","timestamp":1497975782000},"page":"1087-1110","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":13,"title":["The Progress in the Research of Antiplatelet Agents (1995\u20132017)"],"prefix":"10.1080","volume":"9","author":[{"given":"Oscar","family":"Benimana","sequence":"first","affiliation":[{"name":"Jiangsu Key Laboratory of Drug Design &amp; Optimization, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing210009, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lulu","family":"Zhao","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory of Drug Design &amp; Optimization, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing210009, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Kong","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory of Drug Design &amp; Optimization, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing210009, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyu","family":"Li","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory of Drug Design &amp; Optimization, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing210009, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhouling","family":"Xie","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory of Drug Design &amp; Optimization, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing210009, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2017,6,20]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.5455\/njppp.2013.3.090420131"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2013.07.008"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.15.53"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2957"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2013.07.002"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2012.02.047"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.968126"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.2174\/187152511798120912"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08180-1"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000130846.46168.03"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.07.056"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.103.2.201"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm1013693"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867053363540"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.6.624"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3466.2007.00027.x"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02598.x"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-869525"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi754"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.07.058"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2005.11.014"},{"issue":"2","key":"e_1_3_2_24_1","first-page":"A326","article-title":"\u201cFirst in human\u201d experience with PRT060128, a new direct-acting, reversible, P2Y12 inhibitor for IV and oral use","volume":"49","author":"Gretler D","year":"2007","unstructured":"Gretler D , ConleyP, AndrePet al. \u201cFirst in human\u201d experience with PRT060128, a new direct-acting, reversible, P2Y12 inhibitor for IV and oral use. J. Am. Coll. Cardiol.49 (Suppl. 2), A326 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"key":"e_1_3_2_25_1","first-page":"A281","article-title":"Modified diadenosine tetraphosphonate derivatives synergistically inhibit platelet activation via both P2Y1 and P2Y12","volume":"51","author":"Chang H","year":"2008","unstructured":"Chang H , YanachkovIB, DixEJet al. Modified diadenosine tetraphosphonate derivatives synergistically inhibit platelet activation via both P2Y1 and P2Y12. J. Am. Coll. Cardiol.51, A281 (2008).","journal-title":"J. Am. Coll. Cardiol."},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2013.04.007"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm400820m"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2014.04.001"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm500588w"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm4013906"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-015-1302-7"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm301708u"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2013.04.041"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2013.05.025"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2014.01.066"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2014.04.011"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm5006226"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht308.P1431"},{"issue":"5","key":"e_1_3_2_39_1","first-page":"13","article-title":"Platelet glycoprotein IIb\/IIIa receptor blockade in coronary artery disease","volume":"35","author":"Michael AL","year":"2000","unstructured":"Michael AL , RobertMC, EricJT. Platelet glycoprotein IIb\/IIIa receptor blockade in coronary artery disease. J. Am. Coll. Cardiol.35 (5), 13\u201323 (2000).","journal-title":"J. Am. Coll. Cardiol."},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-004-3756-4"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08022-4"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.25.1006"},{"issue":"8","key":"e_1_3_2_43_1","first-page":"105","article-title":"Platelet glycoprotein IIb\/IIIa-receptor inhibitors in patients with acute coronary syndromes or undergoing percutaneous coronary interventions","volume":"23","author":"Kate MT","year":"2001","unstructured":"Kate MT , KwadwoA, SuzanK. Platelet glycoprotein IIb\/IIIa-receptor inhibitors in patients with acute coronary syndromes or undergoing percutaneous coronary interventions. Clin. Ther.23 (8), 105\u2013112 (2001).","journal-title":"Clin. Ther."},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(01)00406-1"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.110.960294"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.2002.3160"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/000331970505600319"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199957030-00015"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.98.13.1268"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1161\/hc0302.102573"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199957020-00009"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mbc.0000164423.90545.a0"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(03)00337-2"},{"issue":"15","key":"e_1_3_2_54_1","first-page":"2363","article-title":"Glycoprotein IIb\/IIIa receptor antagonists in the management of cardiovascular diseases","volume":"55","author":"Pangh C","year":"1998","unstructured":"Pangh C , PharmD. Glycoprotein IIb\/IIIa receptor antagonists in the management of cardiovascular diseases. Am. J. Health-Syst. Ph.55 (15), 2363\u20132386 (1998).","journal-title":"Am. J. Health-Syst. Ph."},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.7.728"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22089"},{"issue":"1","key":"e_1_3_2_57_1","first-page":"81","article-title":"Clinical importance of antiplatelet drugs in cardiovascular diseases","volume":"53","author":"Papp J","year":"2013","unstructured":"Papp J , KenyeresP, TothK. Clinical importance of antiplatelet drugs in cardiovascular diseases. Clin. Hemorheol. Micro.53 (1\u20132), 81\u201396 (2013).","journal-title":"Clin. Hemorheol. Micro."},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.4.340"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703943"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH11-10-0727"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-281154"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm990418b"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(01)00529-7"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2012.04898.x"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2014.07.007"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm060108a"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm200980u"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1021\/ml5002085"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1021\/cb8002094"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvt276"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm9005912"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm070704k"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm800180e"},{"key":"e_1_3_2_74_1","first-page":"1","article-title":"PAR-1 antagonists: an emerging antiplatelet drug class","volume":"148","author":"Pan H","year":"2016","unstructured":"Pan H , BoucherM, KaunelisD. PAR-1 antagonists: an emerging antiplatelet drug class. CADTH148, 1\u201317 (2016).","journal-title":"CADTH"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm900553j"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13455"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf5294"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm010001h"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2014.08.021"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b00928"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm4020026"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13254"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12265-012-9435-y"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S46458"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH13-06-0490"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.112.301013"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7387"}],"container-title":["Future Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4155\/fmc-2017-0001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T19:51:58Z","timestamp":1716493918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.4155\/fmc-2017-0001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":85,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.4155\/fmc-2017-0001"],"URL":"https:\/\/doi.org\/10.4155\/fmc-2017-0001","relation":{},"ISSN":["1756-8919","1756-8927"],"issn-type":[{"value":"1756-8919","type":"print"},{"value":"1756-8927","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmc20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmc20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-01-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-04-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}